BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...
BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today upcoming presentations, ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby ...
Acoramidis (Attruby) shows strong clinical data and rapid launch, but faces tough competition from Pfizer’s tafamidis and upcoming RNAi drugs. BBIO’s pipeline is diverse with multiple late-stage ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby ...
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...
In as few as 3 months, the time to first event (ACM or CVH) durably separated relative to placebo A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 A 50% ...
Recent discussions on X about BridgeBio Pharma (BBIO) have centered around the company's strong performance and analyst endorsements. Many users are highlighting the initiation of coverage by major ...
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results